They concluded that measuring bcl-2 expression in tumor biopsies was an independent predictor of breast cancer outcomes and could be useful as a prognostic adjunct to NPI, particularly in the first 5 years after diagnosis. The gene discussed is BCL2; the disease is breast carcinoma.